

## **Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024**

**DENVER, CO / January 23, 2024** / Aytu BioPharma, Inc. (the Company or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference taking place virtually on February 1, 2024.

### **Company Webcast**

The webcasted fireside chat will take place at 11:45am ET on Thursday, February 1, 2024. The webcast can be accessed at <https://wsw.com/webcast/lytham10/aytu/2125040> or on the Company’s website at <https://investors.aytubio.com/>. The webcast will also be available for replay following the event.

### **1×1 Meetings**

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at [1x1@lythampartners.com](mailto:1x1@lythampartners.com) or register for the event at <https://lythampartners.com/select2024invreg/>.

Further information on the conference is available at <https://lythampartners.com/select2024>.

### **About Aytu BioPharma, Inc.**

Aytu BioPharma is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics. The Company’s prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. To learn more, please visit [aytubio.com](http://aytubio.com).

### **Contacts for Investors:**

Mark Oki, Chief Financial Officer  
Aytu BioPharma, Inc.  
[moki@aytubio.com](mailto:moki@aytubio.com)

Robert Blum or Roger Weiss

Lytham Partners  
AYTU@lythampartners.com

**SOURCE:** Aytu BioPharma, Inc.

View the original press release on [accesswire.com](https://www.accesswire.com)